Approval was based on data from 3 placebo-controlled clinical trials evaluating the efficacy and safety of azelastine HCl nasal spray 0.1% in 322 patients with seasonal allergic rhinitis ...

Read the Patient Information Leaflet if available from your pharmacist before you start using ipratropium and each time you get a refill. Learn how to use this spray properly. If you have any ...

The resulting repeated need for nasal spray isn’t technically considered ... Sprays that contain the antihistamine azelastine (Astepro) are also safe to use and do not create dependence, Dr ...

2-Year U.S. Treasury Note Continuous Contract $101.434 0.008 0.01% 5-Year U.S. Treasury Note Continuous Contract $104.805 0.016 0.01% 10-Year U.S. Treasury Note Continuous Contract $107.375 0.016 ...

2-Year U.S. Treasury Note Continuous Contract $101.559 0.012 0.01% 5-Year U.S. Treasury Note Continuous Contract $105.094 0.055 0.05% 10-Year U.S. Treasury Note Continuous Contract $107.828 0.094 ...

That's 6.5% on travel purchased through Chase Travel, 4.5% on dining and drugstores, and 3% on all other ... card benefits and 0% intro APR offer while earning unlimited 1.5% cashback on all ...

cefotetan disodium injectable EQ 1 gm base/vial and EQ 2 gm base/vial; and flunisolide metered spray 0.029 mg/spray. News, August 17, 2007 First-Time Generic Approvals: Dantrium, Lexapro Capsules ...

March 29, 2024 On the sidelines at NATO’s 75th birthday commemoration last week in Brussels, attendees commiserated about a potential Trump 2.0, and talked about “Trump-proofing” the ...

(Reuters) -Leading German economic institutes have slashed their joint forecast for growth in Germany this year, to 0.1% from a previous 1.3%, sources familiar with the matter told Reuters on Monday.

such as TobraDex ® (tobramycin 0.3%/dexamethasone 0.1%) (Alcon, Ft. Worth, TX), and Maxitrol ® (dexamethasone, neomycin, and polymyxin B) (Alcon, Ft. Worth, TX) are frequently used after ocular ...

Shares have added about 3.1% in that time frame ... Operating revenues rose 0.6% year over year to $285 million in the quarter under review. The top line beat the consensus mark by 2%.